Cutter & CO Brokerage, Inc. Sage Therapeutics, Inc. Transaction History

Cutter & CO Brokerage, Inc.

$406 Million
Q3 2024

18 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 May 03, 2022	SELL	$30.71 - $45.71 $151,830 - $225,990	-4,944 Closed	0 $0
Q4 2021 Feb 10, 2022	SELL	$37.06 - $47.11 $63,002 - $80,087	-1,700 Reduced 25.59%	4,944 $210,000
Q3 2021 Nov 02, 2021	SELL	$40.26 - $57.37 $32,167 - $45,838	-799 Reduced 10.73%	6,644 $294,000
Q2 2021 Aug 09, 2021	SELL	$54.88 - $79.29 $13,445 - $19,426	-245 Reduced 3.19%	7,443 $423,000
Q1 2021 May 11, 2021	SELL	$70.65 - $96.76 $171,608 - $235,030	-2,429 Reduced 24.01%	7,688 $575,000
Q4 2020 Feb 03, 2021	SELL	$58.41 - $89.06 $42,230 - $64,390	-723 Reduced 6.67%	10,117 $875,000
Q3 2020 Nov 05, 2020	BUY	$41.13 - $62.45 $24,390 - $37,032	593 Added 5.79%	10,840 $663,000
Q2 2020 Aug 10, 2020	BUY	$25.95 - $43.15 $59,425 - $98,813	2,290 Added 28.78%	10,247 $426,000
Q1 2020 May 05, 2020	BUY	$26.15 - $77.24 $17,468 - $51,596	668 Added 9.16%	7,957 $229,000
Q4 2019 Feb 11, 2020	BUY	$60.18 - $154.77 $56,870 - $146,257	945 Added 14.9%	7,289 $526,000
Q2 2019 Jul 31, 2019	BUY	$157.85 - $183.09 $20,520 - $23,801	130 Added 2.09%	6,344 $1.16 Million
Q1 2019 Apr 23, 2019	BUY	$89.33 - $163.65 $40,645 - $74,460	455 Added 7.9%	6,214 $988,000
Q4 2018 Feb 07, 2019	BUY	$81.94 - $139.71 $77,761 - $132,584	949 Added 19.73%	5,759 $552,000
Q3 2018 Oct 12, 2018	SELL	$138.11 - $169.04 $69,055 - $84,520	-500 Reduced 9.42%	4,810 $679,000
Q1 2018 May 11, 2018	BUY	$152.15 - $192.33 $18,258 - $23,079	120 Added 2.31%	5,310 $855,000
Q4 2017 Jan 30, 2018	SELL	$60.72 - $167.34 $2,185 - $6,024	-36 Reduced 0.69%	5,190 $855,000
Q3 2017 Oct 23, 2017	SELL	$61.4 - $88.52 $4,298 - $6,196	-70 Reduced 1.32%	5,226 $326,000
Q2 2017 Aug 07, 2017	BUY	N/A	5,296	5,296 $422,000

Others Institutions Holding SAGE

# of Institutions

198

Shares Held

46.5M

Call Options Held

402K

Put Options Held

209K

View Full List

About Sage Therapeutics, Inc.

Ticker SAGE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 59,422,300
Market Cap $323M
Description
Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes medicines to treat central nervous system disorders. Its lead product candidate is ZULRESSO, an intravenous formulation of brexanolone for the treatment of postpartum depression (PPD) in adults. The company's product pipeline also includes zuranolone, a neuroactive...

More about SAGE

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Cutter & CO Brokerage, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Cutter & CO Brokerage, Inc. with notifications on news.

Account